Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel rosaxostat intermediate and novel preparation method of rosaxostat

A technology for roxadustat and intermediates, which is applied in the field of synthesis of pharmaceutical intermediates, can solve the problems of long production cycle, complicated reaction operation, increased cost and the like, and achieves high product purity and yield, mild reaction conditions and easy operation. Effect

Pending Publication Date: 2022-05-24
HANGZHOU HEZE PHARMA TECH +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In summary, the drawbacks of the prior art are that the reaction operation is complicated, the yield is extremely low, and the production cycle is long
The pressure on environmental protection and safe production is high, the cost is greatly increased, and the process has major defects, so it is not suitable for industrial production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel rosaxostat intermediate and novel preparation method of rosaxostat
  • Novel rosaxostat intermediate and novel preparation method of rosaxostat
  • Novel rosaxostat intermediate and novel preparation method of rosaxostat

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Preparation of methyl 2-acetamido-3-oxo-3-(4-phenoxyphenyl) propionate (Ⅲ-a)

[0041] 20.0 g (0.063 mol) of methyl 2-acetamido-3-(4-phenoxyphenyl) propionate (II-a) was dissolved in 200 ml of acetone, and the temperature was lowered to -78°C with stirring. 30.1g (3.0e.q.) of potassium permanganate and 25.5g (2.5e.q.) of ferric chloride were sequentially added, and the reaction was incubated for 2 hours. The temperature was then slowly raised to room temperature and stirring was continued for 12 hours. The reaction solution was diluted with 100 ml of dichloromethane and filtered, the filter cake was rinsed with 100 ml of dichloromethane, the dichloromethane phases were combined, dried over anhydrous magnesium sulfate, decolorized with activated carbon, filtered and concentrated to obtain an off-white solid 2-acetylamino -18.7 g of methyl 3-oxo-3-(4-phenoxyphenyl) propionate (III-a), yield: 89.5%.

[0042] 1H NMR (400MHz DMSO): δ=1.920(s,3H); 3.662(s,3H); 5.932(d,1H); ...

Embodiment 2

[0044] Preparation of ethyl 2-acetamido-3-oxo-3-(4-phenoxyphenyl)propanoate (Ⅲ-b)

[0045] 10.2 g of potassium bromate and 3.2 g of cerium dioxide were dissolved in 100 ml of dioxane solution and stirred at room temperature for five minutes, and ethyl 2-acetamido-3-(4-phenoxyphenyl) propionate (II-b) was added. After 20.0 g (0.061 mol), the temperature was raised to 95° C., and the reaction was maintained for 1 hour. After cooling to room temperature, the reaction solution was filtered, and extracted with dichloromethane and water. The dichloromethane phase was separated, washed with saturated brine, the dichloromethane phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a pale yellow solid 2-acetamido-3-oxo-3-(4- Ethyl phenoxyphenyl)propionate (III-b) 19.0 g, yield: 91.1%.

[0046] 1 H NMR (400MHz DMSO): δ=1.236(t,3H); 1.928(s,3H); 4.219(q,2H); 5.934(d,1H); 7.066(d,2H); 7.176(d,2H) ; 7.188 (d, 1H); 7.429 (t, 2H); 8.652 (s, 1H). ...

Embodiment 3

[0048] Preparation of isopropyl 2-acetamido-3-oxo-3-(4-phenoxyphenyl) propionate (Ⅲ-c)

[0049] Dissolve 20.0 g (0.059 mol) of isopropyl 2-acetamido-3-(4-phenoxyphenyl) propionate (II-c) in 100 ml of tert-butanol, and stir 15.9 g of tert-butyl hydroperoxide. g, the temperature was raised to reflux (85° C.), after the reaction was completed, the tert-butanol was evaporated under reduced pressure to obtain a yellow oil. Add 200ml to dissolve, wash twice with saturated brine (100ml×2), separate the dichloromethane phase, dry with anhydrous magnesium sulfate, and concentrate under pressure to obtain a pale yellow solid 2-acetamido-3-oxo- Isopropyl 3-(4-phenoxyphenyl)propanoate (III-c) 18.5 g, yield: 88.2%.

[0050] 1 H NMR (400MHz DMSO): δ=1.20(d,6H); 1.945(s,3H); 4.944(m,1H); 5.947(d,1H); 7.074(d,2H); 7.183(d,2H) ; 7.192 (d, 1H); 7.431 (t, 2H); 8.660 (s, 1H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a novel rosaxostat intermediate and a novel preparation method of rosaxostat. The novel rosaxostat intermediate shown in the formula (III) is prepared by oxidizing the novel rosaxostat intermediate shown in the formula (II), and the novel rosaxostat intermediate shown in the formula (III) is subjected to amidation and cyclization to prepare rosaxostat. The synthetic route has the advantages of short reaction steps, simple process, mild reaction conditions, high product purity and yield, and suitableness for industrial production.

Description

technical field [0001] The invention belongs to the technical field of synthesis of pharmaceutical intermediates, in particular to a new roxadustat intermediate for treating renal anemia and a new preparation method of roxadustat. Background technique [0002] Renal anemia (CKD) is a long-term progressive disease characterized by loss of renal function, ultimately leading to end-stage renal disease. Anemia is a common complication in patients with CKD. The main drugs for the treatment of anemia associated with chronic kidney disease are erythropoiesis-stimulating agents (ESAs) and recombinant erythropoietin (EPO). However, ESAs have the risk of increasing the risk of cardiovascular adverse reactions, and controlling the content of EPO by regulating the expression of hypoxia-inducible factor (HIF) in the body can increase the formation of hemoglobin in the blood and increase the content of blood cells in the body. Therefore, the treatment of oral HIF inhibitors has more pot...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07C233/47C07C231/12C07D217/26
CPCC07C233/47C07D217/26Y02P20/55
Inventor 倪晟杨政和夏金强付勇朱明月胡小兰卢辰颖赵航徐兵勇周亮
Owner HANGZHOU HEZE PHARMA TECH